CN111050797B - 抗tim-3抗体及其用途 - Google Patents

抗tim-3抗体及其用途 Download PDF

Info

Publication number
CN111050797B
CN111050797B CN201880050603.9A CN201880050603A CN111050797B CN 111050797 B CN111050797 B CN 111050797B CN 201880050603 A CN201880050603 A CN 201880050603A CN 111050797 B CN111050797 B CN 111050797B
Authority
CN
China
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880050603.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN111050797A (zh
Inventor
王明晗
邹晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Van Enshi Pharmaceutical Beijing Co ltd
Original Assignee
Van Enshi Pharmaceutical Beijing Co ltd
Vance Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Van Enshi Pharmaceutical Beijing Co ltd, Vance Pharmaceutical filed Critical Van Enshi Pharmaceutical Beijing Co ltd
Publication of CN111050797A publication Critical patent/CN111050797A/zh
Application granted granted Critical
Publication of CN111050797B publication Critical patent/CN111050797B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880050603.9A 2017-07-28 2018-07-26 抗tim-3抗体及其用途 Active CN111050797B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538277P 2017-07-28 2017-07-28
US62/538,277 2017-07-28
PCT/US2018/043800 WO2019023410A1 (en) 2017-07-28 2018-07-26 ANTI-TIM-1 ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
CN111050797A CN111050797A (zh) 2020-04-21
CN111050797B true CN111050797B (zh) 2024-04-30

Family

ID=65040974

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050603.9A Active CN111050797B (zh) 2017-07-28 2018-07-26 抗tim-3抗体及其用途

Country Status (9)

Country Link
US (1) US11214615B2 (enExample)
EP (2) EP4039274A1 (enExample)
JP (1) JP2021500916A (enExample)
KR (1) KR20200032156A (enExample)
CN (1) CN111050797B (enExample)
AU (1) AU2018306321A1 (enExample)
CA (1) CA3070295A1 (enExample)
EA (1) EA202090401A1 (enExample)
WO (1) WO2019023410A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12454574B2 (en) 2018-10-30 2025-10-28 Board Of Regents, The University Of Texas System Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof
WO2021051352A1 (zh) * 2019-09-19 2021-03-25 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
JP7900284B2 (ja) * 2019-12-17 2026-08-04 フェインズ セラピューティクス，インコーポレーテッド 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用
EP4084826A2 (en) * 2019-12-30 2022-11-09 University Of Louisville Research Foundation, Inc. Virus-like particle binding agents, related compositions, and related methods
WO2021169948A1 (zh) * 2020-02-24 2021-09-02 苏州恒康生命科学有限公司 Tim3结合分子及其应用
US20230183371A1 (en) * 2020-04-30 2023-06-15 Board Of Regents, The University Of Texas System Anti-cd79b antibodies and chimeric antigen receptors and methods of use thereof
GB202015115D0 (en) * 2020-09-24 2020-11-11 Imperial College Innovations Ltd ZIP12 Antibody
CN113151186B (zh) * 2021-02-04 2022-02-18 上海交通大学 抗人cd271的单克隆抗体及用途
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
WO2023105528A1 (en) * 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
CN116925216B (zh) * 2022-04-11 2024-09-24 东莞市朋志生物科技有限公司 抗血清淀粉样蛋白a抗体、检测血清淀粉样蛋白a的试剂和试剂盒
WO2025035133A1 (en) * 2023-08-10 2025-02-13 Board Of Regents, The University Of Texas System Bmp-7 antibody compositions & methods for treating cancer
CN119264251B (zh) * 2024-12-09 2025-03-14 上海交通大学医学院附属仁济医院 一种cbln1单克隆抗体和应用
CN120590523B (zh) * 2025-06-20 2026-01-27 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种犬瘟热病毒n蛋白单克隆抗体，快速检测胶体金试纸条及其制备方法
CN120623323B (zh) * 2025-06-23 2026-04-21 江苏东抗生物医药科技有限公司 一种靶向猴痘病毒的抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132991A (zh) * 2014-01-31 2016-11-16 诺华股份有限公司 针对tim‑3的抗体分子及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR20070094890A (ko) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 안티 ａｄｄｌ 항체 및 그 용도
US9416165B2 (en) 2007-10-26 2016-08-16 The Regents Of The University Of California Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN103173412B (zh) * 2012-12-07 2015-04-22 天津三箭生物技术有限公司 小鼠抗人cd20单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR102060540B1 (ko) 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
CA2913052A1 (en) * 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
AU2015340056A1 (en) 2014-10-27 2017-05-25 Agency For Science, Technology And Research Anti-TIM-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
MY193661A (en) 2014-11-06 2022-10-24 Hoffmann La Roche Anti-tim3 antibodies and methods of use
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2016229189A1 (en) 2015-03-06 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind TIM3
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
US20180271861A1 (en) 2015-07-14 2018-09-27 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132991A (zh) * 2014-01-31 2016-11-16 诺华股份有限公司 针对tim‑3的抗体分子及其用途

Also Published As

Publication number Publication date
JP2021500916A (ja) 2021-01-14
EP3658185A1 (en) 2020-06-03
CA3070295A1 (en) 2019-01-31
KR20200032156A (ko) 2020-03-25
WO2019023410A1 (en) 2019-01-31
US11214615B2 (en) 2022-01-04
CN111050797A (zh) 2020-04-21
US20210032330A1 (en) 2021-02-04
EP4039274A1 (en) 2022-08-10
AU2018306321A1 (en) 2020-02-13
EP3658185A4 (en) 2021-07-14
EA202090401A1 (ru) 2020-05-18

Similar Documents

Publication Publication Date Title
JP7636483B2 (ja) 抗ｃｄ７３抗体及びその使用
US11214615B2 (en) Anti-TIM-3 antibodies and uses thereof
US11401329B2 (en) Anti-CD47 antibodies and uses thereof
CN112584860B (zh) 抗dll3抗体及其用途
CN111050792B (zh) 抗lag-3抗体及其用途
CN111836644A (zh) 抗密蛋白18.2抗体及其用途
CN111954681B (zh) 抗叶酸受体1抗体及其用途
CN111886024A (zh) 抗tip-1抗体及其用途
HK40017927A (en) Anti-tim-3 antibodies and uses thereof
HK40119299A (en) Anti-cd73 antibodies and uses thereof
HK40108974A (en) Anti-btla antibodies and uses thereof in treating cancer
HK40031477A (en) Anti-cd73 antibodies and uses thereof
HK40033064B (en) Anti-folate receptor 1 antibodies and uses thereof
HK40019844A (en) Anti-lag-3 antibodies and uses thereof
HK40031477B (zh) 抗cd73抗体及其用途
HK40033064A (en) Anti-folate receptor 1 antibodies and uses thereof
HK40039992A (en) Anti-dll3 antibodies and uses thereof
HK40030398A (en) Anti-tip-1 antibodies and uses thereof
KR20260013511A (ko) 암 치료를 위한 조합 요법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200410

Address after: 3 / F and 4 / F, office building 3, zone a, Zhongda Marine Biotechnology R & D base, No. 9, Xincheng Avenue, Songshan Lake high tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant after: Dongguan Fanshi biomedical Co.,Ltd.

Address before: California, USA

Applicant before: Vance pharmaceutical

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017927

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240304

Address after: Room 2218, 2nd Floor, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 101111

Applicant after: Van Enshi Pharmaceutical (Beijing) Co.,Ltd.

Country or region after: China

Address before: 523808 Floor 3 and 4, Office Building 3, Zone A, Zhongda Marine Biotechnology R&D Base, No. 9, Xincheng Avenue, Dongguan Songshan Lake Hi tech Industrial Development Zone, Dongguan, Guangdong

Applicant before: Dongguan Fanshi biomedical Co.,Ltd.

Country or region before: China

CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: China

Address after: Room 2218, 2nd Floor, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Tongzhou District, Beijing, 101111

Applicant after: Van Enshi Pharmaceutical (Beijing) Co.,Ltd.

Address before: Room 2218, 2nd Floor, Building 2, No. 88 Kechuang 6th Street, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 101111

Applicant before: Van Enshi Pharmaceutical (Beijing) Co.,Ltd.

Country or region before: China

GR01 Patent grant
GR01 Patent grant